ArticleBlood cancer journal2024
Global, regional, and national burden of Burkitt lymphoma from 1990 to 2021 and predictions to 2030: a systematic analysis for the Global Burden of Disease Study 2021.
Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- [Analysis of the disease burden of Burkitt lymphoma in China from 1990 to 2021].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Burden of Middle-Aged and Elderly Patients With Non-Hodgkin Lymphoma From 1990 to 2021: A Systematic Analysis Based on the Global Burden of Disease 2021.Cancer medicine · 2026Article
- The global landscape of non-Hodgkin lymphoma incidence and mortality in 2022 and projections to 2045.Archives of medical science : AMS · 2026Article
- Proteomic analysis of Burkitt lymphoma tissues: insights into the impact of age and EBV infection on protein expression and molecular characteristics.Discover oncology · 2025Article
- Survival Prediction in Middle-Aged and Elderly Patients With Burkitt Lymphoma: A Comprehensive Nomogram Approach Based on SEER Data.Cancer medicine · 2025Article
- Novel Molecular Insights and Evolution of Less Toxic Therapeutic Strategies in Burkitt Lymphoma.Cancers · 2025Review
- Erbium oxide nanoparticles induce potent cell death, genomic instability and ROS-mitochondrial dysfunction-mediated apoptosis in U937 lymphoma cells.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Patterns of incident Burkitt lymphoma during the HIV epidemic among the Black African and White population in South Africa.British journal of cancer · 2025Article
- Global burden of childhood Burkitt lymphoma (1990-2021): epidemiological trends, regional disparities, and projections for 2035 from the Global Burden of Disease Study.Frontiers in medicine · 2025Article
- Article
- 1990-2041 Global burden of Burkitt lymphoma with 20 years forecast: A systematic analysis using the global burden disease of study of 2021.SAGE open medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.